StreetInsider.com News Articles

Rakovina adds Yale brain tumor expert to scientific advisory board

Thu, 17 Sep 2026 04:30:21 -0400

Rakovina Therapeutics Inc. (TSX-V: RKV, FSE: 7JO0) has appointed Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board, according to a company statement. Dr. Bindra is the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine.

Dr. Bindra's research focuses on DNA repair vulnerabilities in cancer, including synthetic lethality in DNA repair-deficient tumors and the therapeutic application of PARP and ATR inhibition. His laboratory published findings in Nature, Nature Genetics, and Science Translational Medicine showing that IDH1/2-mutant tumors carry a DNA repair defect that makes

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

Thu, 17 Sep 2026 04:30:00 -0400

VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scientific Director of the Yale Brain Tumor Center and the Harvey and Kate Cushing Professor of Therapeutic Radiology at the Yale School of Medicine.

“Dr. Bindra is a leader in the discovery, development and application of cancer therapies in the DNA-damage response field, and his appointment comes at an important

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

Thu, 17 Sep 2026 04:30:00 -0400

“Dr. Bindra is a leader in the discovery, development and application of cancer therapies in the DNA-damage response field, and his appointment comes at an important

Rakovina Therapeutics adds neuro-oncology professor to its board

Thu, 10 Sep 2026 04:00:22 -0400

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has appointed Prof. Petra Hamerlik to its board of directors, following a vote at the company's annual general meeting held on August 18, 2026, in Toronto, Ontario.

Prof. Hamerlik holds the Chair of Translational Neuro-Oncology at the University of Manchester and has served on Rakovina's Scientific Advisory Board since November 2023. She previously held a joint role as Principal Scientist and CNS Cancer Bioscience Lead at AstraZeneca, where she contributed to the development of brain-penetrant DNA repair inhibitors for primary brain tumors and brain metastases.

Before AstraZeneca, she was Group Leader of the Brain Tumour

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

Thu, 10 Sep 2026 04:00:00 -0400

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Prof. Petra Hamerlik to its board of directors at the Company’s annual general meeting of shareholders held on August 18, 2026, in Toronto, Ontario (see news release dated August 19, 2026).

Prof. Hamerlik is the Chair of Translational Neuro-Oncology at the University of Manchester. She and has served on Rakovina’s Scientific Advisory Board (the “SAB”) since November 20, 2023. Prof. Hamerlik

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

Thu, 10 Sep 2026 04:00:00 -0400

Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

Mon, 31 Aug 2026 19:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the three and six months ended June 30, 2026 (“Q2 2026” and “YTD 2026”, respectively), and provided an update on recent corporate developments.

Q2 2026 Financial Highlights

Research and development (R&D) expenses of $1,130,259 for Q2 2026 and $2,161,815 YTD 2026, compared to $1,611,985 in the same period in 2025,

Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

Mon, 31 Aug 2026 19:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q2 2026 Financial Highlights

Research and development (R&D) expenses of $1,130,259 for Q2 2026 and $2,161,815 YTD 2026, compared to $1,611,985 in the same period in 2025,

Rakovina Therapeutics closes $1.99M non-brokered private placement

Mon, 31 Aug 2026 16:12:58 -0400

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) has completed the second and final tranche of its non-brokered private placement, raising aggregate gross proceeds of $1,991,000 across both tranches, according to a press release statement.

The second tranche consisted of 5,970,000 units priced at $0.10 per unit, generating $597,000. The first tranche of 13,940,000 units, which closed on Aug. 12, 2026, raised $1,394,000. In total, the company issued 19,910,000 units under the offering.

Each unit includes one common share and one-half of one common share purchase warrant. Each whole warrant allows the holder to purchase one additional share at $0.20 for 24 months

Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

Mon, 31 Aug 2026 16:12:00 -0400

VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026 and upsized on August 12, 2026.

The Second Tranche consisted of 5,970,000 units (“Units”) at a price of $0.10 per Unit for gross proceeds of $597,000. Together with the first tranche of 13,940,000 Units for gross proceeds of $1,394,000,

Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

Mon, 31 Aug 2026 16:12:00 -0400

VANCOUVER, British Columbia, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, is pleased to announce that it has closed the second and final tranche (the “Second Tranche”) of its previously announced non-brokered private placement (the “Offering”), initially announced on July 15, 2026 and upsized on August 12, 2026.

Rakovina Therapeutics Announces Results from 2026 Annual General Meeting